In-Person vs Electronic Directly Observed Therapy for Tuberculosis Treatment Adherence: A Randomized Noninferiority Trial
Joseph Burzynski, Joan M Mangan, Chee Kin Lam, Michelle Macaraig, Marco M Salerno, B Rey deCastro, Neela D Goswami, Carol Y Lin, Neil W Schluger, Andrew Vernon, eDOT Study Team, Sapna Bamrah-Morris, Sheridan Bowers, Shannon Carberry, Christine Chuck, Matthew Dias, Grace Gao, Richard Garfein, Vernard Green, Lon Gross, Gary Henry, Andrew Hill, Sarah Kiskadden-Bechtel, Meena Lakshman, Nikolaos Mitropoulos, Diana M Nilsen, Margaret Oxtoby, Patrick Philips, Michael Reaves, Errol Robinson, Charlene Sathi, Brock Stewart, Anila Thomas, Zhanna Tolochko, Lisa Trieu, Carla Winston, Joseph Burzynski, Joan M Mangan, Chee Kin Lam, Michelle Macaraig, Marco M Salerno, B Rey deCastro, Neela D Goswami, Carol Y Lin, Neil W Schluger, Andrew Vernon, eDOT Study Team, Sapna Bamrah-Morris, Sheridan Bowers, Shannon Carberry, Christine Chuck, Matthew Dias, Grace Gao, Richard Garfein, Vernard Green, Lon Gross, Gary Henry, Andrew Hill, Sarah Kiskadden-Bechtel, Meena Lakshman, Nikolaos Mitropoulos, Diana M Nilsen, Margaret Oxtoby, Patrick Philips, Michael Reaves, Errol Robinson, Charlene Sathi, Brock Stewart, Anila Thomas, Zhanna Tolochko, Lisa Trieu, Carla Winston
Abstract
Importance: Electronic directly observed therapy (DOT) is used increasingly as an alternative to in-person DOT for monitoring tuberculosis treatment. Evidence supporting its efficacy is limited.
Objective: To determine whether electronic DOT can attain a level of treatment observation as favorable as in-person DOT.
Design, setting, and participants: This was a 2-period crossover, noninferiority trial with initial randomization to electronic or in-person DOT at the time outpatient tuberculosis treatment began. The trial enrolled 216 participants with physician-suspected or bacteriologically confirmed tuberculosis from July 2017 to October 2019 in 4 clinics operated by the New York City Health Department. Data analysis was conducted between March 2020 and April 2021.
Interventions: Participants were asked to complete 20 medication doses using 1 DOT method, then switched methods for another 20 doses. With in-person therapy, participants chose clinic or community-based DOT; with electronic DOT, participants chose live video-conferencing or recorded videos.
Main outcomes and measures: Difference between the percentage of medication doses participants were observed to completely ingest with in-person DOT and with electronic DOT. Noninferiority was demonstrated if the upper 95% confidence limit of the difference was 10% or less. We estimated the percentage of completed doses using a logistic mixed effects model, run in 4 modes: modified intention-to-treat, per-protocol, per-protocol with 85% or more of doses conforming to the randomization assignment, and empirical. Confidence intervals were estimated by bootstrapping (with 1000 replicates).
Results: There were 173 participants in each crossover period (median age, 40 years [range, 16-86 years]; 140 [66%] men; 80 [37%] Asian and Pacific Islander, 43 [20%] Black, and 71 [33%] Hispanic individuals) evaluated with the model in the modified intention-to-treat analytic mode. The percentage of completed doses with in-person DOT was 87.2% (95% CI, 84.6%-89.9%) vs 89.8% (95% CI, 87.5%-92.1%) with electronic DOT. The percentage difference was -2.6% (95% CI, -4.8% to -0.3%), consistent with a conclusion of noninferiority. The 3 other analytic modes yielded equivalent conclusions, with percentage differences ranging from -4.9% to -1.9%.
Conclusions and relevance: In this trial, the percentage of completed doses under electronic DOT was noninferior to that under in-person DOT. This trial provides evidence supporting the efficacy of this digital adherence technology, and for the inclusion of electronic DOT in the standard of care.
Trial registration: ClinicalTrials.gov Identifier: NCT03266003.
Conflict of interest statement
Conflict of Interest Disclosures: Drs Mangan, Lam, deCastro, Goswami, Lin, and Vernon reported employment with the US Centers for Disease Control and Prevention outside the submitted study. No other disclosures were reported.
Figures
References
- Hopewell PC. Tuberculosis control: how the world has changed since 1990. Bull World Health Organ. 2002;80(6):427.
- Weis SE, Slocum PC, Blais FX, et al. . The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med. 1994;330(17):1179-1184. doi:10.1056/NEJM199404283301702
- Suárez PG, Watt CJ, Alarcón E, et al. . The dynamics of tuberculosis in response to 10 years of intensive control effort in Peru. J Infect Dis. 2001;184(4):473-478. doi:10.1086/322777
- Alipanah N, Jarlsberg L, Miller C, et al. . Adherence interventions and outcomes of tuberculosis treatment: a systematic review and meta-analysis of trials and observational studies. PLoS Med. 2018;15(7):e1002595. doi:10.1371/journal.pmed.1002595
- Nahid P, Dorman SE, Alipanah N, et al. . Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis. 2016;63(7):e147-e195. doi:10.1093/cid/ciw376
- Toczek A, Cox H, du Cros P, Cooke G, Ford N. Strategies for reducing treatment default in drug-resistant tuberculosis: systematic review and meta-analysis. Int J Tuberc Lung Dis. 2013;17(3):299-307. doi:10.5588/ijtld.12.0537
- Frieden TR, Sbarbaro JA. Promoting adherence to treatment for tuberculosis: the importance of direct observation. Bull World Health Organ. 2007;85(5):407-409. doi:10.2471/BLT.06.038927
- Moonan PK, Quitugua TN, Pogoda JM, et al. . Does directly observed therapy (DOT) reduce drug resistant tuberculosis? BMC Public Health. 2011;11:19. doi:10.1186/1471-2458-11-19
- Frieden TR, Fujiwara PI, Washko RM, Hamburg MA. Tuberculosis in New York City—turning the tide. N Engl J Med. 1995;333(4):229-233. doi:10.1056/NEJM199507273330406
- Bayer R, Wilkinson D. Directly observed therapy for tuberculosis: history of an idea. Lancet. 1995;345(8964):1545-1548. Published correction appears in Lancet 1995 Jul 29;346(8970):322. doi:10.1016/S0140-6736(95)91090-5
- Chaulk CP, Kazandjian VA. Directly observed therapy for treatment completion of pulmonary tuberculosis: consensus statement of the Public Health Tuberculosis Guidelines Panel. JAMA. 1998;279(12):943-948. Published correction appears in JAMA 1998 Jul 8;280(2):134. doi:10.1001/jama.279.12.943
- Laurence YV, Griffiths UK, Vassall A. Costs to health services and the patient of treating tuberculosis: a systematic literature review. Pharmacoeconomics. 2015;33(9):939-955. doi:10.1007/s40273-015-0279-6
- Tanimura T, Jaramillo E, Weil D, Raviglione M, Lönnroth K. Financial burden for tuberculosis patients in low- and middle-income countries: a systematic review. Eur Respir J. 2014;43(6):1763-1775. doi:10.1183/09031936.00193413
- Ngwatu BK, Nsengiyumva NP, Oxlade O, et al. . The impact of digital health technologies on tuberculosis treatment: a systematic review. Eur Respir J. 2018;51(1):1701596. doi:10.1183/13993003.01596-2017
- Falzon D, Timimi H, Kurosinski P, et al. . Digital health for the End TB Strategy: developing priority products and making them work. Eur Respir J. 2016;48(1):29-45. doi:10.1183/13993003.00424-2016
- Division of Tuberculosis Elimination. Implementing an Electronic Directly Observed Therapy (eDOT) Program: A Toolkit for Tuberculosis Programs. US Centers for Disease Control and Prevention . Updated April 6, 2017. Accessed December 17, 2020.
- Lee Y, Raviglione MC, Flahault A. Use of digital technology to enhance tuberculosis control: scoping review. J Med Internet Res. 2020;22(2):e15727. doi:10.2196/15727
- Story A, Aldridge RW, Smith CM, et al. . Smartphone-enabled video-observed versus directly observed treatment for tuberculosis: a multicentre, analyst-blinded, randomised, controlled superiority trial. Lancet. 2019;393(10177):1216-1224. doi:10.1016/S0140-6736(18)32993-3
- Ravenscroft L, Kettle S, Persian R, et al. . Video-observed therapy and medication adherence for tuberculosis patients: randomised controlled trial in Moldova. Eur Respir J. 2020;56(2):2000493. doi:10.1183/13993003.00493-2020
- Guo P, Qiao W, Sun Y, Liu F, Wang C. Telemedicine technologies and tuberculosis management: a randomized controlled trial. Telemed J E Health. 2020;26(9):1150-1156. doi:10.1089/tmj.2019.0190
- Adewole OO, Oladele T, Osunkoya AH, et al. . A randomized controlled study comparing community based with health facility based direct observation of treatment models on patients’ satisfaction and TB treatment outcome in Nigeria. Trans R Soc Trop Med Hyg. 2015;109(12):783-792. doi:10.1093/trstmh/trv091
- Cavalcante SC, Soares EC, Pacheco AG, Chaisson RE, Durovni B; DOTS Expansion Team . Community DOT for tuberculosis in a Brazilian favela: comparison with a clinic model. Int J Tuberc Lung Dis. 2007;11(5):544-549.
- van den Boogaard J, Lyimo R, Irongo CF, et al. . Community vs. facility-based directly observed treatment for tuberculosis in Tanzania’s Kilimanjaro region. Int J Tuberc Lung Dis. 2009;13(12):1524-1529.
- Zhang H, Ehiri J, Yang H, Tang S, Li Y. Impact of community-based DOT on tuberculosis treatment outcomes: a systematic review and meta-analysis. PLoS One. 2016;11(2):e0147744. doi:10.1371/journal.pone.0147744
- Wright CM, Westerkamp L, Korver S, Dobler CC. Community-based directly observed therapy (DOT) versus clinic DOT for tuberculosis: a systematic review and meta-analysis of comparative effectiveness. BMC Infect Dis. 2015;15:210. doi:10.1186/s12879-015-0945-5
- Munsiff SS, Nilsen D, Fujiwara PI. Clinical Policies and Protocols Bureau of Tuberculosis Control, 4th Edition. New York City Department of Health and Mental Hygiene . Published March 2008. Accessed September 1, 2020.
- PASS Sample Size Software. Non-Inferiority Tests for the Difference Between Two Proportions—Chapter 210. NCSS Statistical Software . Published 2015. Accessed December 15, 2021.
- Chow S, Shao J, Wang H, Lokhnygina Y. Sample Size Calculations in Clinical Research. 2nd ed. Chapman & Hall; 2008:90.
- Agresti A. Categorical Data Analysis. 3rd ed. Wiley; 2013.
- Efron B, Tibshirani RJ. An Introduction to the Bootstrap. 1st ed. Chapman & Hall; 1994. doi:10.1201/9780429246593
- Haberer JE, Subbaraman R. Digital technology for tuberculosis medication adherence: promise and peril. Ann Am Thorac Soc. 2020;17(4):421-423. doi:10.1513/AnnalsATS.202001-027ED
- Imperial MZ, Nahid P, Phillips PPJ, et al. . A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis. Nat Med. 2018;24(11):1708-1715. Published correction appears in Nat Med. 2019 Jan;25(1):190. doi:10.1038/s41591-018-0224-2
Source: PubMed